Mucoepidermoid Carcinoma of the Palate in Adolescence
To evaluate a new prognostic scoring system to delineate survival benefit for patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) undergoing ytrrium-90 radioembolization (Y90).
To study characteristics of HCC patients with malignant portal vein thrombosis (PVT)treated with yttrium-90 radioembolization (Y90), who achieved longer than expected survival outcomes to determine best candidates for therapy.
We have previously described synthesis of a bispecific fusion protein for catheter-directed targeting of glypican-3 (GPC3) expressed on hepatocellular carcinoma (HCC) tumors and CD3 T-cell receptors (GPC3-CD3-bsAb) (1). We hypothesized that in vivo optical fluorescent imaging of GPC3 in mouse models of human HCC would enable effective monitoring of adoptive immunotherapy mediated by GPC3-CD3-bsAb.
The Oncopig Cancer Model (OCM) is a unique transgenic porcine model that develops inducible site and cell specific tumors, and permits in vitro pharmacologic screening using cell lines with the ability to translate promising strategies to in vivo using solid organ tumors. To validate OCM utility for in vitro drug screening, this study tested the hypothesis that OCM and human hepatocellular carcinoma (HCC) cell lines exhibit similar expression of drug-metabolizing enzymes (DMEs) and comparable dose response to standard chemotherapies.
Quiescent stellate cell (Q-HSC) condition media has been shown to induce apoptosis in hepatocellular carcinoma (HCC) cell lines . This in-vitro study investigates the added benefit of retinoic acid (stored in Q-HSCs) co-administration with doxorubicin on HCC tumor cell death. This may help to develop a potential therapeutic option for more effective HCC treatment.
We have previously reported development and synthesis of a novel T-cell redirecting bispecific antibody (bsAb) for catheter-directed targeting of glypican-3 (GPC3) on hepatocellular carcinoma (HCC) tumor cells and T-cell CD3 receptors (1). The purpose of the current study was to further investigate the efficacy of this bsAb for the activation of T-cells as well as for the induction of cytotoxicity towards HCC tumor cells in-vitro.
Retrospective comparison of conventional versus drug-eluting beads transarterial chemoembolization prior to microwave ablation (MWA) in patients with hepatocellular carcinoma (HCC).
To assess the safety and efficacy of using 40-90 micron radiopaque drug-eluting microspheres (M0 LUMI, BTG) for the treatment of hepatocellular carcinoma (HCC) during transarterial chemoembolization (TACE).
In North America the most common causes of hepatocellular carcinoma (HCC) are viral hepatitis and alcohol, however with the rise in obesity non-alcoholic steatohepatitis (NASH) induced HCC is becoming more frequent. Transarterial chemoembolization (TACE) has been proven to be an effective therapy in the treatment of HCC, however, to date little data on treatment outcomes of NASH induced HCC treated by TACE is available. Given cirrhotic livers are known to tolerate embolization more than non-cirrhotics it is possible that patients with NASH induced HCC would experience more complications than other patients treated with TACE.
Caffeic acid (CA) is a natural phytochemical with lethal effects against hepatocellular carcinoma in vitro. However, efficacy requires high locoregional concentrations. Currently available porous hydrogel beads are derivatized with sulfonic acid groups and at neutral pH these negatively charged groups provide binding sites for the cationic drug doxorubicin. A loading protocol was developed for these drug-eluting beads to retain and release neutralized CA for embolic delivery. Pharmacokinetic analysis in an animal model compared loaded beads to an alternative embolic delivery method.